Sold as Coumadin, Athrombin, Panwarfin. Every FDA application for this active ingredient: 3 branded and 18 generic.
As of Nov 16, 2026, FDA lists 21 applications for Warfarin Sodium (sold as Coumadin, Athrombin, Panwarfin), first approved Jun 8, 1954, with 2 new uses approved and 0 published complete response letters.
| Warfarin Sodium | Part D | $38.9M | -11% | 795,666 |
| Jantoven | Part D | $2.7M | -14% | 72,851 |
| An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 SubstratesUlcerative Colitis, Crohn's Disease · Sanofi | Phase 1 | Not yet recruiting | Nov 6, 2026 |
| Post Pulmonary Embolism In Patients Treated With Catheter Based TherapyPulmonary Embolism Acute · Assiut University | Not applicable | Not yet recruiting | Oct 21, 2026 |
| Anticoagulant Cessation After Antiphospholipid Autoantibodies Loss in Thrombotic Antiphospholipid SyndromeAntiphospholipid Syndrome, Thrombotic Antiphospholipid Syndrome · Assistance Publique - Hôpitaux de Paris | Phase 3 | Not yet recruiting | Oct 15, 2026 |
| A Study on Abnormal Menstrual Bleeding in Chinese Women of Childbearing Age Taking Antithrombotic Drugs After Cardiovascular SurgeryUterine Hemorrhage, Cardiovascular Diseases · Shanghai Zhongshan Hospital | — | Recruiting | Oct 13, 2026 |
| Warfarin Quality, Adherence, Range, Determinants, and Events in Egyptian Rheumatic Heart Disease and Atrial FibrillationAF · Assiut University | — | Not yet recruiting | Sep 17, 2026 |
| Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or ObesityDrug Drug Interaction (DDI), Pharmacokinetics and Pharmacodynamics · The United Bio-Technology (Hengqin) Co., Ltd. | Phase 1 | Recruiting | Aug 25, 2026 |
| Predicting Response and Exposure Changes in Cirrhosis for EffectivenessLiver Cirrhosis · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Not applicable | Not yet recruiting | Aug 6, 2026 |
| Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic StrokeIschemic Stroke, Transient Ischemic Attack · Asan Medical Center | Phase 3 | Not yet recruiting | Jul 28, 2026 |
| Jun 8, 1954 | CoumadinNDA 9218 · New molecular entity | Bristol Myers Squibb | 62 | Discontinued |
| Aug 11, 1972 | PanwarfinNDA 17020 · New formulation or manufacturer | Abbott | 10 | Discontinued |
| Mar 26, 1997 | Warfarin SodiumANDA 40145 | Barr | 47 | Discontinued |
| Sep 30, 1997 | Warfarin SodiumANDA 40196 | Chartwell Rx | 10 | Discontinued |
| Jul 15, 1999 | Warfarin SodiumANDA 40301 | Taro | 16 | Marketed |
| Oct 2, 2003 | JantovenANDA 40416 | Upsher Smith Labs | 10 | Marketed |
| Sep 27, 2004 | Warfarin SodiumANDA 40415 | Aurobindo Pharma USA | 7 | Discontinued |
| May 30, 2006 | Warfarin SodiumANDA 40663 | Zydus Pharms USA | 8 | Marketed |
| Jul 5, 2006 | Warfarin SodiumANDA 40616 | Pliva | 7 | Marketed |
| May 25, 2011 | Warfarin SodiumANDA 90935 | Invagen Pharms | 4 | Marketed |
| Mar 4, 2013 | Warfarin SodiumANDA 202202 | Amneal Pharms | 4 | Marketed |
| Jun 27, 2013 | Warfarin SodiumANDA 200104 | Aiping Pharm Inc | 4 | Discontinued |
| — | Warfarin SodiumANDA 86118 | Watson Labs | 0 | Discontinued |
| — | Warfarin SodiumANDA 86119 | Watson Labs | 0 | Discontinued |
| — | Warfarin SodiumANDA 86120 | Watson Labs | 0 | Discontinued |
| — | Warfarin SodiumANDA 86122 | Watson Labs | 0 | Discontinued |
| — | Warfarin SodiumANDA 86123 | Watson Labs | 0 | Discontinued |
| — | Warfarin SodiumANDA 88719 | Usl Pharma | 0 | Discontinued |
| — | Warfarin SodiumANDA 88720 | Usl Pharma | 0 | Discontinued |
| — | Warfarin SodiumANDA 88721 | Usl Pharma | 0 | Discontinued |
| — | Athrombin, Athrombin-KNDA 11771 | Pharm Res Assoc | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA